Article

Enzyme Expression Could Worsen Parkinson's Disease Progression

Increased expression of c-Abl increased α-synuclein clumps in the brain of patients with Parkinson’s disease.

Researchers have found that blocking the enzyme c-Abl can potentially prevent Parkinson’s disease in mice and a chemical tag on the protein α-synuclein could indicate the disease.

"There were indications that c-Abl activity leads to Parkinson's disease, and our experiments show there is indeed a connection," said researcher Ted Dawson, MD, PhD. "There is already a Food and Drug Administration-approved c-Abl inhibiting drug in use for leukemia, so we're interested in whether it could be used safely against Parkinson's disease or as a starting point to develop other treatments."

In a study published by The Journal of Clinical Investigation, researchers engineered mice without the gene for c-Abl, and found that their symptoms were reduced. Mice with increased c-Abl showed worsened symptoms and faster disease progression.

Researchers also found that unmodified mice with an increased production of c-Abl developed the disease. They then examined how c-Abl effects α-synuclein, a protein that clumps in the brain of patients with Parkinson’s disease.

According to the study, c-Abl adds a phosphate group to a specific place on α-synuclein, and they also found that greater expression of c-Abl increased clumping that then worsened symptoms.

"We plan to look into whether α-synuclein with a phosphate group on the spot c-Abl targets could serve as a measure of Parkinson's disease severity," Dr Dawson concluded.

Related Videos
Happy elderly patient with medical health checkup with cardiologist or geriatric doctor. Senior old aging woman with coronary artery heart disease or cardiac illness check-up in clinic - Image credit: Chinnapong | stock.adobe.com
Pharmacist and patient in a retail/community pharmacy setting -- Image credit: Zamrznuti tonovi | stock.adobe.com
5 experts in this video